此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Feasibility of a Community-Based Multimodal Exercise Programme in Parkinson's Disease

2026年9月30日 更新者:Mario González Iglesias、Universidad Rey Juan Carlos

Feasibility and Preliminary Effectiveness of an Individualised Multimodal Group-Based Exercise Programme for People With Parkinson's Disease: A Non-Randomized Feasibility Study

This study aims to evaluate the feasibility and preliminary effectiveness of a multimodal, group-based but individualised therapeutic exercise programme for people with Parkinson's disease delivered within a real-world community-based patient association setting.

The primary objective is to assess the feasibility of implementing the programme, including recruitment, consent, adherence, intervention completion, acceptability, perceived exertion and safety. Secondary objectives are to obtain preliminary comparative information regarding the effects of the intervention on motor and non-motor symptoms, physical fitness, pain-related outcomes and exercise-induced hypoalgesia.

This is a non-randomized sequential feasibility study including an intervention group participating in a 12-week multimodal exercise programme and a matched non-exercise control group maintaining usual activities. Outcomes will be assessed at baseline, post-intervention and 6-month follow-up.

研究概览

地位

招聘中

详细说明

Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder characterised by motor symptoms such as bradykinesia, rigidity and tremor, as well as non-motor symptoms including pain, fatigue, sleep disturbances, cognitive impairment and psychiatric symptoms. Although pharmacological management is effective for several motor manifestations, many non-motor symptoms respond poorly to dopaminergic therapy, highlighting the need for complementary non-pharmacological interventions.

Exercise therapy has shown beneficial effects on both motor and non-motor symptoms in people with Parkinson's disease. However, it remains necessary to determine whether exercise programmes supported by the scientific literature can be feasibly implemented within real-world community environments frequently attended by patients, such as Parkinson's disease associations. In these settings, exercise interventions are commonly delivered in generic group-based formats despite the substantial heterogeneity in symptom severity, functional capacity and disease progression among participants. Therefore, there is also a need to design exercise programmes that allow individualised adjustment of exercise prescription parameters, including intensity and progression criteria, in order to optimize the potential effects of exercise on Parkinson's disease symptoms while maintaining safety and feasibility in community-based group settings.

The present study aims to evaluate the feasibility of implementing a multimodal, group-based but individualised therapeutic exercise programme within a real-world Parkinson's disease association setting. Feasibility outcomes include consent and recruitment rates, adherence, intervention completion, trial completion, acceptability, perceived exertion, treatment-decision rate and safety. Control group recruitment and assessment completion will be reported descriptively as operational information related to the exploratory comparison group, but they will not determine the primary feasibility assessment of the intervention.

Secondary objectives are to obtain preliminary comparative information regarding the potential effectiveness of the intervention on motor and non-motor symptoms, gait, balance, physical fitness, pain-related outcomes and exercise-induced hypoalgesia.

This study uses a non-randomized sequential feasibility design. Recruitment of the intervention group as a cohort was necessary to implement the group exercise programme under realistic conditions and to evaluate intervention-related feasibility outcomes. To provide preliminary comparative information regarding effectiveness, a matched non-exercise control group was included.

Frequency matching will be used at the group level according to sex, 10-year age categories and Hoehn & Yahr stage categories (1-1.5, 2-2.5 and 3). Individual 1:1 matching will not be required. This approach was selected to reduce baseline imbalance while maintaining the feasibility of recruitment within a real-world community setting.

The sample size was determined according to the primary feasibility objective, specifically the precision of the estimated adherence rate. Assuming an expected adherence rate of approximately 80%, 28 participants would provide an estimation precision of approximately ±15% with a 95% confidence interval. Considering potential attrition, the intervention group sample size was increased to 32 participants. A matched non-exercise control group of 32 participants will also be recruited, resulting in a total target sample size of 64 participants.

Participants with Hoehn & Yahr stages 1-3 will be recruited from Asociación Parkinson Madrid and other Parkinson's disease associations in the Madrid region.

The intervention group will participate in a 12-week multimodal exercise programme consisting of two weekly supervised face-to-face sessions and one weekly home-based session. The programme includes strength training, cardiovascular/balance exercise and cognitive-motor exercises. Exercise prescription and progression were individualised according to participant tolerance, functional capacity, motor performance, and safety considerations.

Training intensity was monitored and adjusted using 10-repetition maximum principles, repetitions in reserve (RIR), and perceived exertion scales including OMNI-RES and Borg ratings. Exercise prescription and progression were individualised according to participant tolerance, functional capacity, motor performance, and safety considerations. All supervised sessions were delivered by physiotherapists experienced in neurological rehabilitation and exercise prescription for Parkinson's disease.

Outcomes will be assessed at baseline, post-intervention and 6-month follow-up.

Feasibility outcomes will be analysed descriptively using frequencies, percentages, means and confidence intervals where appropriate. Secondary clinical outcomes measured at baseline, post-intervention and 6-month follow-up will be analysed using linear mixed-effects models including group, time and group-by-time interaction effects. Estimated between-group differences, 95% confidence intervals and effect sizes will be reported. Given the feasibility nature of the study and the non-randomized sequential design, efficacy analyses will be interpreted as exploratory and hypothesis-generating rather than confirmatory.

研究类型

介入性

注册 (估计的)

64

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Mario González Iglesias, MSc PhD Student, Physiotherapy
  • 电话号码:+34 622 113 365
  • 邮箱:mario.gonzalez@urjc.es

研究联系人备份

  • 姓名:Yeray González Zamorano, PhD, Physiotherapy
  • 电话号码:+34 689 105 357
  • 邮箱:yeray.gonzalez@urjc.es

学习地点

    • Madrid
      • Alcorcón、Madrid、西班牙、28922
        • 招聘中
        • Universidad Rey Juan Carlos

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Eligibility Criteria The eligibility criteria will be identical for both the experimental and control groups. However, this study will employ a sequential recruitment design. To provide preliminary comparative information regarding effectiveness, a matched non-exercise control group was included. Frequency matching will be used at the group level according to sex, 10-year age categories and Hoehn & Yahr stage categories (1-1.5, 2-2.5 and 3). Individual 1:1 matching will not be required.

Inclusion Criteria:

  • Subjects diagnosed with Idiopathic Parkinson's Disease according to the UK Parkinson's Disease Society Brain Bank Diagnostic Criteria.
  • Subjects staged between 1 and 3 on the Hoehn & Yahr Scale. For matching purposes, stage 1 includes stage 1.5, and stage 2 includes stage 2.5.

Exclusion Criteria:

  • Subjects diagnosed with a neurological disease other than PD.
  • Those diagnosed with a cardiovascular, respiratory, or metabolic disease or other conditions that represent a contraindication to physical exercise.
  • Those who have suffered an exacerbation or hospitalization in the last three months prior to starting the assessment protocol or during the therapeutic intervention process.
  • Those who have received a course of steroids, intravenously or orally, six months prior to the start of the study or during the therapeutic intervention process.
  • Those with cognitive impairment (defined as a score < 21 on the Montreal Cognitive Assessment, MoCA) or language impairments that prevent adequate communication, comprehension, or following of exercise instructions.
  • Participation in a structured, individualized strength and/or aerobic exercise program within the three months prior to enrollment.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Exercise group

Two weekly in-person sessions of multimodal exercise that involve strength training, aerobic interval training / balance and coordination training and a cognitive-motor exercise, each session lasting 55-60 minutes. Additionally, one weekly home session lasting 25-30 minutes that include strength and aerobic training.

In-person session structure: 1) Warm-up for 4 minutes; 2) 4 strength exercises for upper limps, trunk and lower limbs with free weights and elastic bands (3 sets per exercise); 3) Moderate to vigorous aerobic interval training / balance and coordination training (4 stations for 40 seconds, 2 sets); 4) Cognitive-motor exercise for 10 minutes; 5) Stretching and cool-down for 3 minutes.

Home session structure: 1) Warm-up for 4 minutes; 2) 3 strength exercises for upper limbs, trunk and lower limbs (3 sets per exercise); 3) Moderate to vigorous aerobic interval training (4 stations for 40 seconds, 2 sets); 4) Stretching and cool-down for 3 minutes

无干预:Control Group

Participants from the control group will be asked to keep their usual treatment for the duration of the study.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Consent rate
大体时间:Baseline

It will be asessed as the proportion of individuals who provided informed consent relative to the number of individuals invited to participate

Baseline
Recruitment rate
大体时间:Baseline

It will be evaluated as the proportion of enrolled participants relative to the number of eligible participants screened

Baseline
Adherence rate
大体时间:Post-intervention (At 12 weeks from the start of the programme)

Adherence rate will be assessed as the proportion of completed sessions relative to the scheduled sessions

Post-intervention (At 12 weeks from the start of the programme)
Intervention completion rate
大体时间:Post-intervention (At 12 weeks from the start of the programme)

It will be evaluated as the proportion of participants who completed at least 80% of sessions.

Post-intervention (At 12 weeks from the start of the programme)
Trial completion rate
大体时间:At 39 weeks from the start of the programme

It will be assessed as the proportion of participants who completed all assessments

At 39 weeks from the start of the programme
Proportion of adverse events
大体时间:Post-intervention (At 12 weeks from the start of the programme)

Safety will be reported as the proportion of adverse events, defined as the proportion of participants who experienced adverse events (e.g., falls, pain, fatigue)

Post-intervention (At 12 weeks from the start of the programme)
Treatment-decision rate
大体时间:Post-intervention (At 12 weeks from the start of the programme)

Defined as the proportion of exercises that required modification due to fall-risk considerations

Post-intervention (At 12 weeks from the start of the programme)
Change in Theoretical Framework Acceptability Questionnaire
大体时间:At 12 weeks from Baseline

It is a questionnaire specifically desgined to assess acceptability of healthcare interventions. It consists of 7 domains: 1) Affective attitude, 2) Burden, 3) Ethicality, 4)Perceived efectiveness, 5) Intervention coherence, 6) Self efficacy, 7) Opportinity costs 8) General acceptability.

At 12 weeks from Baseline
Client Satisfaction Questionnaire (CSQ-8)
大体时间:Post-intervention (12 weeks from baseline)

It contains 8 dimensions measuring satisfaction with the care and treatment received. The total score is 32 points, with higher scores indicating greater satisfaction. Dimensions related to satisfaction with the training modality and tool used (entertainment, ease of use, accessibility, among others), the professional who applies it (clear explanation, availability, ability to adapt, among others) or recommendation to other patients will be evaluated.

Post-intervention (12 weeks from baseline)
Average Rating of Perceived Exertion (RPE) during Resistance Training
大体时间:Through study completion (average across 12 weeks)

The average perceived effort reported by the participants across all strength training sessions over the 12-week intervention. This will be assessed using the OMNI-Resistance Exercise Scale (OMNI-RES), which ranges from 0 ("extremely easy") to 10 ("extremely hard"). Higher scores indicate a greater perception of effort during the execution of strength exercises

Through study completion (average across 12 weeks)
Average Rating of Perceived Exertion (RPE) during Cardiorespiratory Exercise
大体时间:Through study completion (average across 12 weeks)

The average intensity of effort perceived by the participants during all cardiorespiratory training sessions. This will be measured using the Borg Rating of Perceived Exertion (RPE) 6-20 Scale. The scale ranges from 6 (no exertion at all) to 20 (maximal exertion). This metric reflects the global subjective strain experienced during aerobic activities throughout the 12-week program.

Through study completion (average across 12 weeks)

次要结果测量

结果测量
措施说明
大体时间
Change in Unified Parkinson Disease Rating Scale Part 3 (UPDRS-3)
大体时间:At 12 weeks from Baseline

This scale evaluates the severity of those motor symptoms linked to the disease such as tremor, rigidity, bradikinesia, postural instability and gait distubances. It consists of 18 items that are scored from 0 (no disturbance) to 4 (maximum disturbance)

At 12 weeks from Baseline
Change in Unified Parkinson Disease Rating Scale Part 3 (UPDRS-3)
大体时间:At 39 weeks from Baseline

This scale evaluates the severity of those motor symptoms linked to the disease such as tremor, rigidity, bradikinesia, postural instability and gait distubances. It consists of 18 items that are scored from 0 (no disturbance) to 4 (maximum disturbance)

At 39 weeks from Baseline
Change in Balance Berg Scale
大体时间:At 12 weeks from Baseline

This scale measures static and dynamic balance through 14 tasks. Each task is scored from 0 (worst score) to 4 (best score)

At 12 weeks from Baseline
Change in Balance Berg Scale
大体时间:At 39 weeks from Baseline

This scale measures static and dynamic balance through 14 tasks. Each task is scored from 0 (worst score) to 4 (best score)

At 39 weeks from Baseline
Change in Non-Motor Symptoms Scale (NMSS)
大体时间:At a 12 weeks from Baseline

It is a 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions: 1) Cardiovascular, 2) Sleep/fatigue, 3) Mood/apathy, 4) Perceptual problems/hallucinations, 5) Attention/memory, 6) Gastrointestinal tract, 7) Urinary, 8) Sexual function and 9) Miscellaneous.

At a 12 weeks from Baseline
Change in Non-Motor Symptoms Scale (NMSS)
大体时间:At a 39 weeks from Baseline

It is a 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease (PD). The NMSS measures the severity and frequency of non-motor symptoms across nine dimensions: 1) Cardiovascular, 2) Sleep/fatigue, 3) Mood/apathy, 4) Perceptual problems/hallucinations, 5) Attention/memory, 6) Gastrointestinal tract, 7) Urinary, 8) Sexual function and 9) Miscellaneous.

At a 39 weeks from Baseline
Change in 10 Repetition Maximum (10-RM)
大体时间:At 12 weeks from Baseline

The 10-RM is the maximum amount of weight a person can lift exactly 10 times with correct technique, without being able to perform an eleventh repetition. 10-RM for military press with dumbbells, lunges with dumbbells, deadlift with barbell and row with barbell will be assessed.

At 12 weeks from Baseline
Change in Isometric Handgrip Strength
大体时间:At 12 weeks from Baseline

A dynamometer is used to measure the maximum handgrip strength with both hands for three times. The mean is obtained after the three attempts.

At 12 weeks from Baseline
Change in Isometric Handgrip Strength
大体时间:At 39 weeks from Baseline

A dynamometer is used to measure the maximum handgrip strength with both hands for three times. The mean is obtained after the three attempts.

At 39 weeks from Baseline
Change in Dynamic Fatigability
大体时间:At 12 weeks from Baseline

A dynamometer is employed and the subject is asked to perform 15 consecutive maximum handgrip contractions.

At 12 weeks from Baseline
Change in Dynamic Fatigability
大体时间:At 39 weeks from Baseline

A dynamometer is employed and the subject is asked to perform 15 consecutive maximum handgrip contractions.

At 39 weeks from Baseline
Change in Five Times Sit to Stand Test
大体时间:At 12 weeks from Baseline

This test measures lower limbs power. The subject is asked to stand up and sit down on a chair as quicky as possible for five times while the therapist measures the time. Two attempts are performed to calculate the mean.

At 12 weeks from Baseline
Change in Five Times Sit to Stand Test
大体时间:At 39 weeks from Baseline

This test measures lower limbs power. The subject is asked to stand up and sit down on a chair as quicky as possible for five times while the therapist measures the time. Two attempts are performed to calculate the mean.

At 39 weeks from Baseline
Change in 6 Minute Walk Test
大体时间:At 12 weeks from Baseline

This test assesses the distance a person is capable to walk as fast as possible for 6 minutes.

At 12 weeks from Baseline
Change in 6 Minute Walk Test
大体时间:At 39 weeks from Baseline

This test assesses the distance a person is capable to walk as fast as possible for 6 minutes on a 15 metres long corridor.

At 39 weeks from Baseline
Change in Functional Movement Screen
大体时间:At 12 weeks from Baseline

This scale consists of seven motor tasks that measure the quality of movement in different body segments. Each task is scored from (worst score) 0 to 3 (best score).

At 12 weeks from Baseline
Change in King´s Parkinson´s Disease Pain Scale score
大体时间:At 12 weeks from Baseline

Parkinson´s Disease specific scale that evaluates the localization, frequency, and intensity of pain. It has 14 items distributed in 7 domains: 1. Musculoskeletal Pain; 2. Chronic Pain; 3. Fluctuation-related Pain; 4. Nocturnal Pain; 5.

Oro-facial Pain; 6. Discoloration, Oedema/Swelling Pain; 7. Radicular Pain. Each item is scored by severity (0, none to 3, very severe) multiplied by frequency (0, never to 4, all the time) resulting in a subscore of 0 to 12, the sum of which gives the total score with a theoretical range from 0 to 168, with higher scores indicating more severity and frequency of pain.

At 12 weeks from Baseline
Change in King´s Parkinson´s Disease Pain Scale score
大体时间:At 39 weeks from Baseline

Parkinson´s Disease specific scale that evaluates the localization, frequency, and intensity of pain. It has 14 items distributed in 7 domains: 1. Musculoskeletal Pain; 2. Chronic Pain; 3. Fluctuation-related Pain; 4. Nocturnal Pain; 5.

Oro-facial Pain; 6. Discoloration, Oedema/Swelling Pain; 7. Radicular Pain. Each item is scored by severity (0, none to 3, very severe) multiplied by frequency (0, never to 4, all the time) resulting in a subscore of 0 to 12, the sum of which gives the total score with a theoretical range from 0 to 168, with higher scores indicating more severity and frequency of pain.

At 39 weeks from Baseline
Change in Brief Pain Inventory
大体时间:At 12 weeks from Baseline

It assess the severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours.

At 12 weeks from Baseline
Change in Brief Pain Inventory
大体时间:At 39 weeks from Baseline

It assess the severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours.

At 39 weeks from Baseline
Change in Pressure Pain Threshold
大体时间:At 12 weeks from Baseline

Two Pain Pressure Thresholds will be measured by a handheld algometer, one over the most painful area (peripheric hyperalgesia) and the other one over the middle of the distal phalanx of the thumb (central hyperalgesia). The Pain Pressure Threshold will be applied with the algometer perpendicular to the skin increasing at a rate of 1 kg/s until the first sensation of pain. 3 measures with 30-seconds rest between them will be performed, taking the average as Pain Pressure Threshold.

At 12 weeks from Baseline
Change in Pressure Pain Threshold
大体时间:At 39 weeks from Baseline

Two Pain Pressure Thresholds will be measured by a handheld algometer, one over the most painful area (peripheric hyperalgesia) and the other one over the middle of the distal phalanx of the thumb (central hyperalgesia). The Pain Pressure Threshold will be applied with the algometer perpendicular to the skin increasing at a rate of 1 kg/s until the first sensation of pain. 3 measures with 30-seconds rest between them will be performed, taking the average as Pain Pressure Threshold.

At 39 weeks from Baseline
Change in Conditioned Pain Modulation
大体时间:At 12 weeks from Baseline

Assesses the descending pain modulatory system. The Pain Pressure Threshold will be assessed in the middle of the distal phalanx of the thumb with a handheld algometer, corresponding to the first test stimulus. Afterward, the patient will immerse the contrary hand up to the wrist into stirred ice-cold water (0-4º) maintaining it for 3 minutes corresponding to the conditioning stimulus. If the pain is unbearable before the 3 minutes, the patient will be able to remove his/her hand. Immediately after removing the hand, a second Pain Pressure Threshold measure will be performed in the same place as the first one, corresponding to the second test stimulus.

At 12 weeks from Baseline
Change in Conditioned Pain Modulation
大体时间:At 39 weeks from Baseline

Assesses the descending pain modulatory system. The Pain Pressure Threshold will be assessed in the middle of the distal phalanx of the thumb with a handheld algometer, corresponding to the first test stimulus. Afterward, the patient will immerse the contrary hand up to the wrist into stirred ice-cold water (0-4º) maintaining it for 3 minutes corresponding to the conditioning stimulus. If the pain is unbearable before the 3 minutes, the patient will be able to remove his/her hand. Immediately after removing the hand, a second Pain Pressure Threshold measure will be performed in the same place as the first one, corresponding to the second test stimulus.

At 39 weeks from Baseline
Change in Exercise-Induced Hypoalgesia
大体时间:At 12 weeks from Baseline

Exercise-Induced Hypoalgesia is a phenomenom in which pain sensitivity is reduced after a single bout of exercise. Pain sensitivity will be assessed before and immediately after the 6 minute walk test. Pain sensitivity will be measured with a handheld algometer on the dominant quadriceps and on the non-dominant trapezius for two times. The algometer will be placed perpendicular to the skin increasing at a rate of 1 kg/s until the first sensation of pain.

At 12 weeks from Baseline
Change in Exercise-Induced Hypoalgesia
大体时间:At 39 weeks from Baseline

Exercise-Induced Hypoalgesia is a phenomenom in which pain sensitivity is reduced after a single bout of exercise. Pain sensitivity will be assessed before and immediately after the 6 minute walk test. Pain sensitivity will be measured with a handheld algometer on the dominant quadriceps and on the non-dominant trapezius for two times. The algometer will be placed perpendicular to the skin increasing at a rate of 1 kg/s until the first sensation of pain.

At 39 weeks from Baseline
Change in Tampa Scale of Kinesiophobia
大体时间:At 12 weeks from Baseline

Measures fear of movement-related pain. Its scores range from 11-44 points with higher scores indicating greater fear of pain, movement, and injury

At 12 weeks from Baseline
Change in Tampa Scale of Kinesiophobia
大体时间:At 39 weeks from Baseline

Measures fear of movement-related pain. Its scores range from 11-44 points with higher scores indicating greater fear of pain, movement, and injury

At 39 weeks from Baseline
Pain Catastrophizing Scale
大体时间:At 12 weeks from Baseline

Measures catastrophizing thinking. Its total score range from 0-52, along with three subscale scores assessing rumination, magnification and helplessness, with higher scores indicating higher level of catastrophizing.

At 12 weeks from Baseline
Pain Catastrophizing Scale
大体时间:At 39 weeks from Baseline

Measures catastrophizing thinking. Its total score range from 0-52, along with three subscale scores assessing rumination, magnification and helplessness, with higher scores indicating higher level of catastrophizing.

At 39 weeks from Baseline
Change In Fatigue Severity Scale
大体时间:At 12 weeks from Baseline

It is a validated 9-item scale for PD that measures the long-term functional impact of fatigue. Each item is scored from 1 (Disagree) to 7 (Agree).

At 12 weeks from Baseline
Change In Fatigue Severity Scale
大体时间:At 39 weeks from Baseline

It is a validated 9-item scale for PD that measures the long-term functional impact of fatigue. Each item is scored from 1 (Disagree) to 7 (Agree).

At 39 weeks from Baseline
Change in Parkinson's Disease Sleep Scale 2 (PDSS-2)
大体时间:At 12 weeks from Baseline

This scale contains 15 items that measures the level of sleep disruption. The questionnaire asks about the frequency of the sleep disturbances from "never" to "very often".

At 12 weeks from Baseline
Change in Parkinson's Disease Sleep Scale 2 (PDSS-2)
大体时间:At 39 weeks from Baseline

This scale contains 15 items that measures the level of sleep disruption. The questionnaire asks about the frequency of the sleep disturbances from "never" to "very often".

At 39 weeks from Baseline
Change in State-Trait Anxiety Inventory
大体时间:At 12 weeks from Baseline

Measures anxious states and anxious traits. It has 20 items for assessing trait anxiety and 20 for state anxiety. All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always"). Higher scores indicate greater anxiety.

At 12 weeks from Baseline
Change in State-Trait Anxiety Inventory
大体时间:At 39 weeks from Baseline

Measures anxious states and anxious traits. It has 20 items for assessing trait anxiety and 20 for state anxiety. All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always"). Higher scores indicate greater anxiety.

At 39 weeks from Baseline
Change in Beck Depression Inventory
大体时间:At 12 weeks from Baseline

Measures depressive symptoms. Scores range from 0 to 63 leading to 6 groups: 0-10, normal; 11-16, mild mood disturbance; 17-20, borderline clinical depression; 21-30, moderate depression; 31-40, severe depression; and over 40, extreme depression.

At 12 weeks from Baseline
Change in Beck Depression Inventory
大体时间:At 39 weeks from Baseline

Measures depressive symptoms. Scores range from 0 to 63 leading to 6 groups: 0-10, normal; 11-16, mild mood disturbance; 17-20, borderline clinical depression; 21-30, moderate depression; 31-40, severe depression; and over 40, extreme depression.

At 39 weeks from Baseline
Change in Global Physical Activity Questionnaire (GPAQ)
大体时间:At 12 weeks from Baseline

It is a questionnaire that consists of 15 questions about physical activity at work, during commutes and in leisure time, and an additional question about sedentary behaviour during a typical week. This questionnaire provides a numerical result in METs, such that the more active the person is, the more METs the instrument reflects.

At 12 weeks from Baseline
Change in Global Physical Activity Questionnaire (GPAQ)
大体时间:At 39 weeks from Baseline

It is a questionnaire that consists of 15 questions about physical activity at work, during commutes and in leisure time, and an additional question about sedentary behaviour during a typical week. This questionnaire provides a numerical result in METs, such that the more active the person is, the more METs the instrument reflects.

At 39 weeks from Baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Mario González Iglesias, Physiotherapy、Universidad Rey Juan Carlos
  • 研究主任:Javier Güeita Rodríguez, Physiotherapy、Universidad Rey Juan Carlos
  • 研究主任:Yeray González Zamorano, Physiotherapy、Universidad Rey Juan Carlos
  • 研究主任:Juan Pablo Romero Muñoz, MD、Universidad Francisco de Vitoria
  • 研究主任:Josué Fernández Carnero, Physiotherapy、Universidad Rey Juan Carlos
  • 研究主任:Alberto Arribas Romano, Physiotherapy、Universidad Rey Juan Carlos

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年9月8日

初级完成 (实际的)

2026年5月29日

研究完成 (估计的)

2027年9月1日

研究注册日期

首次提交

2026年5月25日

首先提交符合 QC 标准的

2026年5月25日

首次发布 (实际的)

2026年6月1日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月30日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Individual anonymized participant data will be available to other researchers under request.

IPD 共享时间框架

Six months at the end of the study.

IPD 共享访问标准

Individual anonymized participant data will be available to other researchers under request.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅